Chiesi Global Rare Diseases receives FDA approval for Filsuvez®
The FDA has finally approved the new topical gel for the treatment of EB in the US. Filsuvez® topical gel is indicated for treating partial thickness wounds in patients six months and older with Junctional and Dystrophic EB. Filsuvez® is the first approved treatment for wounds associated with JEB. EMA approved the gel in June 2022. See news article.
Find out more on Chiesi's website.